Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Common Equity (2023 - 2025)

Onconetix (ONCO) has disclosed Common Equity for 2 consecutive years, with $41.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Common Equity rose 300.75% to $41.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $41.0 million, a 300.75% increase, with the full-year FY2023 number at $1.4 million, changed N/A from a year prior.
  • Common Equity was $41.0 million for Q3 2024 at Onconetix, up from -$28.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $41.0 million in Q3 2024 to a low of -$28.7 million in Q2 2024.